Adapsyn’s proprietary drug discovery platform will be applied to the screening of bacteria to discover neuro- and immunomodulatory small molecules to develop therapeutic agents for the treatment of ch...
Adapsyn Bioscience Inc.
6 enregistrements totalisant 1,256,473.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $955,473 | 5 enregistrements |
| Agence fédérale de développement économique pour le Sud de l'Ontario | $301,000 | 1 enregistrement |
Enregistrements
RRRF funding will be used to support Recipients to address the impacts of the COVID-19 pandemic.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
Bacterial strains from the human microbiome will be screened for the production of secondary metabolites with the potential to influence the human nervous and immune systems, for potential application...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.